Experts discuss how treatment strategies for NSCLC differ between resectable and metastatic disease, emphasizing a multimodal, curative approach in early-stage cancer versus personalized systemic ...

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced results from a study, where Cellworks' biosimulation ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

With the evolving landscape of metastatic non-small cell lung cancer (NSCLC) treatment, standardized guidelines are invaluable in patient management. Current treatment strategies depend on the ...

Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Non-small cell lung cancer (NSCLC) patients with advanced disease receiving standard of care treatment have a higher overall survival (OS) than similar patients not receiving treatment. Lung cancer is ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...